United Therapeutics (NASDAQ:UTHR) Price Target Raised to $660.00
by Kim Johansen · The Markets DailyUnited Therapeutics (NASDAQ:UTHR – Free Report) had its price objective lifted by HC Wainwright from $600.00 to $660.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for United Therapeutics’ Q1 2026 earnings at $6.77 EPS, Q2 2026 earnings at $6.76 EPS and Q3 2026 earnings at $6.74 EPS.
Several other analysts have also weighed in on the company. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Bank of America increased their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, TD Cowen upped their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $586.00.
View Our Latest Stock Analysis on UTHR
United Therapeutics Price Performance
NASDAQ UTHR opened at $564.81 on Tuesday. The business has a fifty day moving average price of $504.78 and a two-hundred day moving average price of $477.55. The stock has a market capitalization of $24.76 billion, a PE ratio of 20.24, a PEG ratio of 1.66 and a beta of 0.75. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $607.89.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the company posted $6.19 EPS. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.
Insider Transactions at United Therapeutics
In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 361,820 shares of company stock valued at $182,730,910. Insiders own 10.30% of the company’s stock.
Institutional Investors Weigh In On United Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at $31,000. Wilmington Savings Fund Society FSB lifted its holdings in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of United Therapeutics during the fourth quarter worth $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
United Therapeutics News Roundup
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Phase‑3 Tyvaso (IPF) results met the study’s key endpoint, a material clinical success that supports revenue upside and longer‑term product expansion for United Therapeutics. This is the primary bullish catalyst behind the recent run‑up. United Therapeutics Is Up After Positive Tyvaso Data
- Positive Sentiment: Multiple sell‑side analysts have reacted favorably: HC Wainwright keeps a Buy and $660 target while tweaking quarterly EPS estimates (raising Q3, trimming Q1/Q2 modestly), and other brokers issued bullish notes/upgrades — supporting a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
- Neutral Sentiment: Options activity is unusually high, suggesting traders are positioning around recent news and earnings risk; this can amplify intraday moves but is not a directional fundamental change. United Therapeutics Target of Unusually High Options Trading
- Neutral Sentiment: Coverage pieces and valuation analysis are appearing (assessments of Tyvaso’s impact on valuation); these shape investor expectations but don’t alter the underlying clinical win. Assessing United Therapeutics Valuation After Tyvaso Results
- Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond all sold multi‑thousand share blocks in late March/early April (sales executed under Rule 10b5‑1 plans). The size and timing of these sales (millions of dollars each) can be interpreted as near‑term negative pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.